These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


100 related items for PubMed ID: 20199181

  • 1. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ.
    Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
    [Abstract] [Full Text] [Related]

  • 2. Lercanidipine in patients with chronic renal failure: the ZAFRA study.
    Robles NR, Ocon J, Gomez CF, Manjon M, Pastor L, Herrera J, Villatoro J, Calls J, Torrijos J, Rodríguez VI, Rodriguez MM, Mendez ML, Morey A, Martinez FI, Marco J, Liebana A, Rincon B, Tornero F.
    Ren Fail; 2005 Jan; 27(1):73-80. PubMed ID: 15717638
    [Abstract] [Full Text] [Related]

  • 3. [Lercanidipine in diabetic patients with renal failure].
    Robles NR, Pastor L, Manjón M, Ocón J, Gómez Campderá F, Herrera J, Villatoro J, Calls J, Torrijos J, Rodríguez Villareal I, Rodríguez Martínez MA, Méndez ML, Morey A, Martínez Fernández J, Marco J, Liébana A, Rincón B, Tornero F.
    Nefrologia; 2004 Jan; 24(4):338-43. PubMed ID: 15455493
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 5. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
    Robles NR, Ruiz Jiménez B, Hernández Gallego R, Ruiz-Calero R, Sánchez Casado E, Cubero JJ.
    Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [Abstract] [Full Text] [Related]

  • 7. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H.
    Clin Exp Hypertens; 2010 Apr; 32(6):400-5. PubMed ID: 20828221
    [Abstract] [Full Text] [Related]

  • 8. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR, Fernandez Carbonero E, Romero B, Sánchez Casado E, Cubero JJ.
    Cardiovasc Ther; 2009 Apr; 27(2):101-7. PubMed ID: 19426247
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T, Pohl M, Misselwitz J, John U.
    Kidney Blood Press Res; 2009 Apr; 32(6):440-4. PubMed ID: 20016211
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 11. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Oct; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Cicero AF, Gerocarni B, Rosticci M, Borghi C.
    Clin Exp Hypertens; 2012 Oct; 34(2):113-7. PubMed ID: 21967031
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of lercanidipine in the general practice setting].
    Robles NR, Canelada JA, Iglesias M, Angulo E, López Acedo A, Díaz Olea E, Cidoncha F, Guerras M, Fuentes J, Garrido J, Lapie J, Peña J, Aguilar A, Hidalgo P.
    An Med Interna; 2003 Jun; 20(6):282-6. PubMed ID: 12848597
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 15. [Doxazosine associated to renin-angiotensin blockers and calcioantagonists in chronic renal failure patients].
    Robles NR, Gómez Campderá F, Ocón I, Manjón M, Pastors L, Herrera J, Villatoro J, Calls I, Torrijos I, Rodríguez Villareal I, Rodríguez Martínez MA, Méndez ML, Morey A, Martínez Fernández I, Marco I, Liébana A, Rincón B, Tornero F.
    Nefrologia; 2005 Apr; 25(5):515-20. PubMed ID: 16392301
    [Abstract] [Full Text] [Related]

  • 16. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 17. Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure.
    Robles NR, Cancho B, Barroso S, Martín MV, Sánchez Casado E.
    Int J Clin Pract; 2006 Sep; 60(9):1035-9. PubMed ID: 16939543
    [Abstract] [Full Text] [Related]

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 19. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G.
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [Abstract] [Full Text] [Related]

  • 20. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Oct; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.